Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

North America’s medical devices industry saw a drop of 10.34% in deal activity during February 2021

29 Mar 2021 (Last Updated March 29th, 2021 19:18)

North America’s medical devices industry saw a drop of 10.34% in deal activity during February 2021, when compared with the last 12-month average, led by Veracyte’s $600m acquisition of Decipher Biosciences, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 78 medical devices industry deals worth $1.76bn were announced for the region in February 2021, against the 12-month average of 87 deals.

Of all the deal types, venture financing saw most activity in February 2021 with 41 transactions, representing a 52.6% share for the region.

In second place was M&A with 31 deals, followed by private equity deals with six transactions, respectively capturing a 39.7% and 7.7% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $831.84m, while venture financing and private equity deals totalled $825.82m and $104.62m, respectively.

North America medical devices industry deals in February 2021: Top deals

The top five medical devices deals accounted for 59.5% of the overall value during February 2021.

The combined value of the top five medical devices deals stood at $1.05bn, against the overall value of $1.76bn recorded for the month.

The top five medical devices industry deals of February 2021 tracked by GlobalData were:

1) Veracyte’s $600m acquisition of Decipher Biosciences

2) The $150m acquisition deal with Simplify Medical by NuVasive

3) DNS Capital, General Catalyst Partners, Glen Tullman, GreatPoint Ventures, TYH Ventures, Wasson Enterprise and Wittington Ventures’ $105m venture financing of Truvian Sciences

4) The $103m venture financing of Personal Genome Diagnostics by Catalio Capital Management, Cowen Healthcare Investments, Innovatus Capital Partners, Kern Capital Management, New Enterprise Associates, Northpond Ventures, PFM Health Sciences, Rock Springs Capital Management, Sands Capital Management, Vensana Capital and Windham Venture Partners

5) Altium Capital, Axiom Associates, Colle Capital Partners, GV Management Co, Huamin Investment Management and Nextrans’ venture financing of Hyperfine Research for $90m.